Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 2,100
Avg Vol 4,588
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 74%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

Astellas Pharma Inc. engages in the research, development, manufacture, sale, and supply of pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYLOY, a treatment for gastric adenocarcinoma and esophagogastric junction adenocarcinoma; and PADCEV, a treatment for patients with metastatic urothelial carcinoma. It also provides VEOZAH, a treatment for vasomotor symptoms associated with menopause;...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 81 3 3244 3000
Address:
2-5-1, Nihonbashi-Honcho, Chuo, Japan
Latest News on ALPMF
No data available.